{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.9","upperLimit":"42.3","value":"23.3"},{"groupId":"OG001","lowerLimit":"15.2","upperLimit":"64.6","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"OROPHARYNGEAL HPV P-16 POSITIVE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"19.4","value":"12.4"},{"groupId":"OG001","lowerLimit":"8.6","upperLimit":"27.9","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"OROPHARYNGEAL HPV P-16 NEGATIVE/ NON-OROPHARYNGEAL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"NUMBER","populationDescription":"All Randomized Participants - Platinum Refractory Subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to end of study. Approximately 63 Months","title":"ORR - Platinum Refractory Subgroup Based on HPV p-16 Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}